Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)
NCT04365257 · Johns Hopkins University · PHASE2 · terminated · last registry update 2023-04-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of recruitment” | – | Registry record, Johns Hopkins University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-05Phase 3 first posted: Opus Genetics, Inc, phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist + Placebo (NCT06349759)
- 2024-02-29Phase 3 first posted: Helwan University, Phentolamine (NCT06286059)
- 2024-02-26Results posted on the registry: VA Office of Research and Development, prazosin hydrochloride + placebo (NCT03221751)
- 2024-02-26Also stopped (terminated): VA Office of Research and Development, prazosin hydrochloride + placebo (NCT03221751)
- 2024-02-15Results posted on the registry: Opus Genetics, Inc, Phentolamine Mesylate Ophthalmic Solution 1% (NCT04004507)
- 2024-02-09Phase 3 first posted: Jimma University, Bromocriptine mesylate plus standard GDMT (NCT06250257)
- 2024-01-23Also stopped (terminated): Otsuka Pharmaceutical Development & Commercialization, Inc., Propranolol + Prazosin (NCT05189977)
- 2023-11-20Results posted on the registry: University of California, Los Angeles, Phenoxybenzamine + Doxazosin (NCT03176693)
- 2023-11-18Also stopped (suspended): Rennes University Hospital, Fludrocortisone + Placebo (NCT05001854)
- 2023-11-02Results posted on the registry: Indiana University, Antidepressant Medications (NCT04437485)
- 2023-10-25Phase 3 first posted: Humanitas Clinical and Research Center, Cannabidiol and β-Caryophyllene Patch (NCT06099171)
- 2023-10-16Phase 3 first posted: University of Aarhus, Noradrenalin + Phenylephrine (NCT06083948)
- 2023-08-21Results posted on the registry: Tulane University School of Medicine, amlodipine, hydralazine, terazosin or hydrochlorothiazide (NCT02046395)
- 2023-08-14Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% (NCT04620213)
- 2023-08-09Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% + Phentolamine Ophthalmic Solution Vehicle (Placebo) (NCT04638660)
- 2023-08-02Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% + Phentolamine Ophthalmic Solution Vehicle (NCT05223478)
- 2023-08-02Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% + Pilocarpine (NCT04675151)
- 2023-08-01Results posted on the registry: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% + Phentolamine Ophthalmic Solution Vehicle (NCT05134974)
- 2023-07-24Results posted on the registry: Satsuma Pharmaceuticals, Inc., Dihydroergotamine + Placebo (NCT04940390)
- 2023-07-14Phase 3 first posted: Milton S. Hershey Medical Center, Oxymetazoline 0.1% (Pf) Oph Soln Ud (NCT05945615)
- 2023-07-12Results posted on the registry: Opus Genetics, Inc, Phentolamine Mesylate Ophthalmic Solution 1% (NCT03960866)
- 2023-07-05Phase 3 first posted: Odense University Hospital, Noradrenaline (NCT05931601)
- 2023-07-03Results posted on the registry: Satsuma Pharmaceuticals, Inc., Dihydroergotamine (NCT04406649)
- 2023-06-29Results posted on the registry: Satsuma Pharmaceuticals, Inc., Dihydroergotamine + Placebos (NCT03901482)
- 2023-04-04Also stopped (withdrawn): Montreal Heart Institute, Bromocriptine (NCT02590601)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision